Valeant, Pershing Square Balk At Draft Class Action Notices
Valeant Pharmaceuticals and Pershing Square Capital Management LP have objected to the notification procedures proposed in a newly certified class action over insider trading claims related to an attempted $55 billion...To view the full article, register now.
Already a subscriber? Click here to view full article